Background: Little is known about the prognostic implications of anemia in patients undergoing elective percutaneous coronary intervention (PCI), especially when they have coexisting chronic kidney disease (CKD).
Methods: We identified 7299 patients who underwent elective PCI from the CREDO-Kyoto registry cohort-2. The primary outcome was 3-year major adverse cardiac events (MACE); composite of all cause death, heart failure hospitalization, and myocardial infarction.
Results: In total, 1466 patients (20.0%) had mild anemia (hemoglobin=11.0-11.9 g/dL for women and 11.0-12.9 g/dL for men), and 740 patients (10.1%) had moderate-to-severe anemia (hemoglobin<11.0 g/dL both for women and for men). Compared to the no-anemia group, cumulative incidence of MACE was significantly higher in the mild and moderate-to-severe anemia groups (7.9%, 20.1%, and 34.2%, respectively). The adjusted hazard ratios of mild and moderate-to-severe anemia versus no-anemia for MACE were 1.77 (95% confidence interval: 1.47-2.15) and 2.53 (95% confidence interval: 2.03-3.14), respectively. In a subgroup analysis, significantly higher risk for MACE was consistently observed with mild and moderate-to-severe anemia both in patients with and without CKD. The risk for MACE showed an accretive increment with exacerbation in either the renal function or anemia (interaction p<0.001).
Conclusions: Even mild anemia was associated with significantly worse 3-year clinical outcomes in patients who underwent elective PCI. Coexisting CKD additively increased the risk for MACE in these patients.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.ijcard.2013.08.029 | DOI Listing |
Malays J Pathol
December 2024
Universiti Sains Malaysia, School of Medical Sciences, Human Genome Centre, Health Campus, Kelantan, Malaysia.
Multiple myeloma (MM), a clonal B-cell neoplasia, is an incurable and heterogeneous disease where survival ranges from a few months to more than 10 years. The clinical heterogeneity of MM arises from multiple genomic events that result in tumour development and progression. Recurring genomic abnormalities including cytogenetic abnormalities, gene mutations and abnormal gene expression profiles in myeloma cells have a strong prognostic power.
View Article and Find Full Text PDFBrain Pathol
December 2024
Laboratory of Neurobiology and Molecular Therapeutics, Department of Neuroscience, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milano, Italy.
Amyotrophic lateral sclerosis (ALS) is a fatal neuromuscular disease with no effective treatments, in part caused by variations in progression and the absence of biomarkers. Mice carrying the SOD1G93A transgene with different genetic backgrounds show variable disease rates, reflecting the diversity of patients. While extensive research has been done on the involvement of the central nervous system, the role of skeletal muscle remains underexplored.
View Article and Find Full Text PDFJ Transl Med
December 2024
Department of Breast Surgery, College of Medicine, The First Affiliated Hospital, Zhejiang University, Hangzhou, 310000, Zhejiang, China.
Background: Aberrant alternative splicing (AS) contributes to tumor progression. A crucial component of AS is cleavage and polyadenylation specificity factor 4 (CPSF4). It remains unclear whether CPSF4 plays a role in triple-negative breast cancer (TNBC) progression through AS regulation.
View Article and Find Full Text PDFBMC Med Imaging
December 2024
Department of Radiology, School of Medicine, University of Health and Allied Sciences (UHAS), Ho, Ghana.
Background: Microcardia and cardiomegaly are good diagnostic and prognostic tools for several diseases. This study investigated the distribution of microcardia and cardiomegaly among students of the University of Health and Allied Sciences (UHAS) in Ghana to determine the prevalence of microcardia and cardiomegaly across gender, and to evaluate the correlation between the presence of these heart conditions and age.
Methods: This retrospective study involved a review of 4519 postero-anterior (PA) chest X-rays (CXRs) between 2020 and 2023.
Sci Rep
December 2024
Department of Neurosurgery, The First Hospital of Hebei Medical University, Shijiazhuang, 050000, Hebei, China.
Six-transmembrane epithelial antigen of prostate 3 (STEAP3), a member of the iron regulation protein family, is characterized by a high recurrence rate and a short survival time. Nevertheless, studies investigating the role of STEAP3 in glioblastoma (GB) are scarce. In this study, the prognostic value of STEAP3 was evaluated utilizing mRNA expression profiles from Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA) databases as the validation and training cohorts, respectively.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!